ZP General Partner 3 ApS: Financial statements 2022
CVR: 41023422
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ZP General Partner 3 ApS (CVR 41023422) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 1,000 and a net result of DKK -24,000 compared with USD -1,000 the year before. The profit margin was -2,400%. Equity in the 2022 report amounted to DKK 22,000. The solvency ratio was 0.8%.
- Revenue
- DKK 1,000
- Gross Profit
- DKK 1,000
- Profit/Loss
- DKK -24,000
- Equity
- DKK 22,000
- Total Assets
- DKK 2,855,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 1K | 1K | -24K | 22K | - |
| 2021 | 0 USD | 0 USD | -1K USD | 7K USD | - |
| 2020 | 280K USD | -279K USD | 218K USD | 245K USD | - |
Official annual report
Keep an eye on ZP General Partner 3 ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of November 1, 2022, Henriette Wennicke is registered as director of ZP General Partner 3 ApS.
As of November 1, 2022, Lykke Jul Rømer has stepped down as director of ZP General Partner 3 ApS.
As of August 31, 2022, Lykke Jul Rømer is registered as director of ZP General Partner 3 ApS.
As of August 31, 2022, Matthew Donald Dallas has stepped down as director of ZP General Partner 3 ApS.
ZP General Partner 3 ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -1,000.
As of March 30, 2022, Adam Sinding Steensberg is registered as director of ZP General Partner 3 ApS.
As of March 30, 2022, Emmanuel Dulac has stepped down as director of ZP General Partner 3 ApS.
About ZP General Partner 3 ApS
ZP General Partner 3 ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The company is owned by ZEALAND PHARMA A/S. In 2025, the company reported revenue of DKK 1,000 and a net result of DKK -29,000 compared with DKK -18,000 the year before. Equity in the 2025 report amounted to DKK 30,000.